SMS Pharmaceuticals Management

Management criteria checks 3/4

SMS Pharmaceuticals' CEO is Ramesh Potluri, appointed in Aug 1990, has a tenure of 33.75 years. total yearly compensation is ₹30.75M, comprised of 97.6% salary and 2.4% bonuses, including company stock and options. directly owns 36.22% of the company’s shares, worth ₹6.16B. The average tenure of the management team and the board of directors is 5 years and 7.9 years respectively.

Key information

Ramesh Potluri

Chief executive officer

₹30.7m

Total compensation

CEO salary percentage	97.6%
CEO tenure	33.8yrs
CEO ownership	36.2%
Management average tenure	5yrs
Board average tenure	7.9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Ramesh Potluri's remuneration changed compared to SMS Pharmaceuticals's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	₹361m
Sep 30 2023	n/a	n/a	₹288m
Jun 30 2023	n/a	n/a	₹150m
Mar 31 2023	₹31m	₹30m	-₹71m
Dec 31 2022	n/a	n/a	-₹42m
Sep 30 2022	n/a	n/a	₹9m
Jun 30 2022	n/a	n/a	₹259m
Mar 31 2022	₹38m	₹26m	₹622m
Dec 31 2021	n/a	n/a	₹789m
Sep 30 2021	n/a	n/a	₹911m
Jun 30 2021	n/a	n/a	₹791m
Mar 31 2021	₹47m	₹21m	₹625m
Dec 31 2020	n/a	n/a	₹458m
Sep 30 2020	n/a	n/a	₹319m
Jun 30 2020	n/a	n/a	₹308m
Mar 31 2020	₹26m	₹20m	₹316m
Dec 31 2019	n/a	n/a	₹386m
Sep 30 2019	n/a	n/a	₹405m
Jun 30 2019	n/a	n/a	₹406m
Mar 31 2019	₹32m	₹20m	₹400m
Mar 31 2018	₹32m	₹20m	₹317m

Compensation vs Market: Ramesh's total compensation ($USD368.79K) is above average for companies of similar size in the Indian market ($USD186.42K).

Compensation vs Earnings: Ramesh's compensation has been consistent with company performance over the past year.

CEO

Ramesh Potluri (65 yo)

33.8yrs

Tenure

₹30,745,000

Compensation

Mr. Ramesh Babu Potluri has been the Chairman and Managing Director of SMS Pharmaceuticals Limited since August 30, 1990. Mr. Potluri has pioneered the vision of developing SMS in to one of the leading Pha...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Ramesh Potluri	Chairman & MD	33.8yrs	₹30.75m	36.22% ₹ 6.2b
Lakshmi Tammineedi	Chief Financial Officer	6.7yrs	₹2.30m	no data
Tumma Thirumalesh	Company Secretary & Compliance Officer	2.3yrs	₹1.49m	no data
Vamsi Potluri	Executive Director	3.3yrs	₹6.69m	15.74% ₹ 2.7b
Y. Rao	Assistant General Manager of HR and Legal	no data	no data	no data
Potluri Kumar	Head of HRD and General Manager of Purchases	no data	no data	no data

5.0yrs

Average Tenure

60yo

Average Age

Experienced Management: 532815's management team is seasoned and experienced (5 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Ramesh Potluri	Chairman & MD	33.8yrs	₹30.75m	36.22% ₹ 6.2b
Vamsi Potluri	Executive Director	3.9yrs	₹6.69m	15.74% ₹ 2.7b
Pakalapati Kumar	Non-Executive & Independent Director	9.8yrs	₹100.00k	0.10% ₹ 17.1m
Neelaveni Thummala	Non-Executive & Independent Director	9.8yrs	₹310.00k	no data
Sarvepalli Srinivas	Non-Executive & Independent Director	4.8yrs	₹100.00k	no data
Shravan Kudaravalli	Non-Executive & Independent Director	6yrs	₹330.00k	0.035% ₹ 6.0m

7.9yrs

Average Tenure

60.5yo

Average Age

Experienced Board: 532815's board of directors are considered experienced (7.9 years average tenure).

SMS Pharmaceuticals Management

Management criteria checks 3/4

Key information

Recent management updates

SMS Pharmaceuticals Limited, Annual General Meeting, Sep 30, 2023

Insufficient new directors

SMS Pharmaceuticals Limited, Annual General Meeting, Sep 30, 2022

Sms Pharmaceuticals Limited Announces Shilpa R Waghmare Ceases to Be A Member of the Board of Directors

SMS Pharmaceuticals Limited Appoints Tirumalesh Tumma as Company Secretary & Compliance Officer

SMS Pharmaceuticals Limited Announces Executive Changes

Recent updates

Investor sentiment improves as stock rises 15%

SMS Pharmaceuticals Limited announced that it has received INR 285.75 million in funding from Potluri Infra Projects Private Limited

Investor sentiment improves as stock rises 17%

Investor sentiment improves as stock rises 15%

SMS Pharmaceuticals Limited announced that it expects to receive INR 285.75 million in funding from Potluri Infra Projects Private Limited

Third quarter 2024 earnings released: EPS: ₹1.36 (vs ₹0.44 in 3Q 2023)

SMS Pharmaceuticals Limited announced that it expects to receive INR 285.75 million in funding from Potluri Infra Projects Private Limited

SMS Pharmaceuticals Limited to Report Q3, 2024 Results on Feb 08, 2024

Second quarter 2024 earnings released: EPS: ₹1.39 (vs ₹0.24 loss in 2Q 2023)

SMS Pharmaceuticals Limited to Report Q2, 2024 Results on Nov 08, 2023

Upcoming dividend of ₹0.30 per share at 0.2% yield

SMS Pharmaceuticals Limited, Annual General Meeting, Sep 30, 2023

First quarter 2024 earnings released: EPS: ₹1.10 (vs ₹1.51 loss in 1Q 2023)

SMS Pharmaceuticals Limited to Report Q1, 2024 Results on Aug 08, 2023

Insufficient new directors

Full year 2023 earnings released: ₹0.83 loss per share (vs ₹7.35 profit in FY 2022)

SMS Pharmaceuticals Limited Recommends Dividend for the Financial Year 2022-2023

SMS Pharmaceuticals Limited to Report Q4, 2023 Results on May 24, 2023

Third quarter 2023 earnings released: EPS: ₹0.44 (vs ₹1.07 in 3Q 2022)

SMS Pharmaceuticals Limited to Report Q3, 2023 Results on Feb 09, 2023

Second quarter 2023 earnings released: ₹0.24 loss per share (vs ₹2.72 profit in 2Q 2022)

Investor sentiment improved over the past week

SMS Pharmaceuticals Limited (BSE:532815) acquired 4.9% stake in Provenio Astral International LLP for INR 0.98 million.

Upcoming dividend of ₹0.30 per share

SMS Pharmaceuticals Limited Recommends for Payment of Dividend for the Financial Year 2021-22, Payable on or after 30th September, 2022

SMS Pharmaceuticals Limited Recommends for Payment of Dividend for the Financial Year 2021-22, Payable on or after 30th September, 2022

First quarter 2023 earnings released: ₹1.51 loss per share (vs ₹2.78 profit in 1Q 2022)

SMS Pharmaceuticals Limited, Annual General Meeting, Sep 30, 2022

Sms Pharmaceuticals Limited Announces Shilpa R Waghmare Ceases to Be A Member of the Board of Directors

SMS Pharmaceuticals Limited to Report Q1, 2023 Results on Aug 13, 2022

SMS Pharmaceuticals Limited Receives CEP Approval for Ibuprofen from the European Directorate for the Quality of Medicines & Healthcare

Full year 2022 earnings released: EPS: ₹7.35 (vs ₹7.39 in FY 2021)

SMS Pharmaceuticals Limited Recommends Dividend for the Financial Year 2021-22

SMS Pharmaceuticals Limited to Report Q4, 2022 Results on May 30, 2022

Investor sentiment improved over the past week

SMS Pharmaceuticals Limited Appoints Tirumalesh Tumma as Company Secretary & Compliance Officer

SMS Pharmaceuticals Limited Announces Executive Changes

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

SMS Pharmaceuticals Limited to Report Q3, 2022 Results on Feb 09, 2022

Second quarter 2022 earnings released: EPS ₹2.72 (vs ₹1.30 in 2Q 2021)

Upcoming dividend of ₹0.30 per share

First quarter 2022 earnings released: EPS ₹2.78 (vs ₹0.83 in 1Q 2021)

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS ₹7.39 (vs ₹3.73 in FY 2020)

SMS Pharmaceuticals Limited Recommends Dividend for the Year 2020-21

Investor sentiment improved over the past week

New 90-day high: ₹135

Third quarter 2021 earnings released: EPS ₹2.53 (vs ₹0.90 in 3Q 2020)

Investor sentiment improved over the past week

New 90-day high: ₹134

SMS Pharmaceuticals Limited to Report Q3, 2021 Results on Feb 10, 2021

New 90-day high: ₹112

New 90-day high: ₹99.15

Non-Executive Director recently sold ₹281m worth of stock

New 90-day low: ₹81.50

SMS Pharmaceuticals Limited to Report Q2, 2021 Results on Nov 03, 2020

New 90-day high: ₹97.85

SMS Pharmaceuticals Limited to Report Q1, 2021 Results on Aug 12, 2020

Earnings released

New 90-day high - ₹86.05

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure